Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Jan;25(1):17-21.
doi: 10.1111/j.1365-2125.1988.tb03276.x.

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients

R R Weber  1 , C E McCoy, J A Ziemniak, E D Frederickson, L I Goldberg, M B Murphy
Affiliations

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients

R R Weber et al. Br J Clin Pharmacol. 1988 Jan.

Abstract

1 The pharmacokinetic properties of intravenous fenoldopam, a selective dopamine1-receptor agonist, were studied in 10 patients with essential hypertension. 2 Reduction in blood pressure was linearly related to the log fenoldopam plasma concentration (r = 0.69) and the log fenoldopam infusion rate (r = 0.71). 3 The mean elimination half-life (+/- s. e. mean) was 9.8 +/- 1.0 min. The total body clearance was 30.3 +/- 2.3 ml kg-1 min-1 and the volume of distribution was 582 +/- 62 ml kg-1. 4 The rapid onset of action, short elimination half-life, linear dose-response relationship, and ease of administration suggest that fenoldopam may have a role where parenteral treatment of hypertension is required.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 1982 Nov;223(2):305-13 - PubMed
    1. Clin Pharmacol Ther. 1983 Sep;34(3):309-15 - PubMed
    1. Circulation. 1984 Jun;69(6):1142-5 - PubMed
    1. Clin Pharmacol Ther. 1987 Mar;41(3):282-8 - PubMed
    1. J Clin Invest. 1984 Dec;74(6):2198-207 - PubMed

Publication types